Merck (MRK) Change in Accured Expenses (2009)
Merck (MRK) posted quarterly Change in Accured Expenses of -$3.8 billion for Q4 2009, down 4692.41% quarter-over-quarter from -$79.0 million in Q3 2009.
Merck (MRK) Change in Accured Expenses (2009) Analysis & Trends
Merck (MRK) has reported Change in Accured Expenses for 1 consecutive years, with -$3.8 billion the latest figure, recorded in Q4 2009.
- In Q4 2009, Change in Accured Expenses changed N/A year-over-year to -$3.8 billion; the TTM figure through Dec 2009 stood at -$3.5 billion (changed N/A YoY), while the FY2025 annual figure was $195.0 million, up 108.38% from the prior year.
- Change in Accured Expenses eased to -$3.8 billion in Q4 2009 per MRK's latest filing, from -$79.0 million in the prior quarter.
- Across five years, Change in Accured Expenses topped out at -$79.0 million in Q3 2009 and bottomed at -$3.8 billion in Q4 2009.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 2.32 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 1.20 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | - |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 852.00 Mn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 338.00 Mn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | - |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | - |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2009 | -3.79 Bn |
| Dec 31, 2009 | -3.79 Bn |
| Sep 30, 2009 | -79.00 Mn |
| Sep 30, 2009 | -79.00 Mn |